The group came to market in 2010 with a compelling story based on dominance of a niche market, good recurring revenues and strong cash generation. Instem, along with many other pharma services companies, is weathering an unforeseen market slowdown. Excluding the Clinical business, performance remains solid, particularly in pre-clinical and the SEND product areas. Management has taken decisive actions to address the weakness in Clinical and a further positive is the emerging opportunity to deliver technology-enabled outsourced services.
Instem sells software products to a variety of customer types involved in the early drug development segment of the healthcare market, and to other life sciences R&D organizations.